CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) today announced an agreement to extend its manufacturing agreement with Fenwal, Inc. for INTERCEPT Blood System products. Under the new agreement, Fenwal will supply Cerus with finished disposable kits for the INTERCEPT platelet and plasma systems through the end of 2013.
